CRO, R&D trends

Jan 2, 2017

CRO industry grows as increasingly complex R&D trends demand advanced expertise

Among today’s CRO, R&D trends, precision-based medicines and immunotherapies for smaller populations and treatments for rare diseases are driving innovation. Aside from the exorbitant costs tied to development, these treatments require advanced and integrated expertise. In an effort to contain costs and shorten development timelines, pharma and biopharma firms increasingly outsource many services associated with the development
of today’s complex therapies into the hands of CROs.

It’s not just complex therapies, but also combination regimens, as well as delivery systems and companion diagnostics that require expert development strategies and protocols. Today, CROs need to be faster, smarter, and more responsive to accommodate these needs. Managing complexity continues to be a top priority for CROs.
The global CRO market, inclusive of early- and late-stage development services is forecasted to grow at a CAGR of 9.8% over the period 2014-2019, according to a recent report published by Infiniti Research Ltd.


About ArisGlobal

ArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® is a unified platform that boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant SaaS architecture.

Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China. For more updates, follow ArisGlobal on LinkedIn and Twitter.

Additional Information

Connect with ArisGlobal on LinkedIn:
Follow @Aris_Global on Twitter:


Erika Thomas
+305-726-6601 |